[Pretreatment with cisplatin plus hyperthermia kills different tumor cells but preserves the erythrocyte function in the intra-operative blood salvage in vitro].

Objective: To investigate the effects of cisplatin plus hyperthermia on erythrocytes and killing human hepatocarcinoma (HepG2), gastro carcinoma (SGC7901) and colonic carcinoma (SW620) cells in the intra-operative blood salvage from cancer surgery in vitro.
Methods: HepG2, SGC7901 or SW620 cells were mixed into the aliquot of erythrocyte concentrated from each intra-operative blood salvage of 30 patients subjected to gastrointestinal cancer surgery. The mixture cells were divided into the following groups (n = 30): A group (37 °C); B group (42 °C); C, D, E groups (50, 100, or 200 µg/ml DDP); F, G, H, I groups (42 °C, 25, 50, 100, or 200 µg/ml DDP). After treating for 60 min, tumor cells and erythrocytes were separated by density gradient centrifugation. The Na(+)-K(+)-ATPase activity, cell count, osmotic fragility, and blood gas variables were determined in erythrocytes. Cell viability and colony formation were determined in tumor cells.
Results: Compared with A [(0.30 ± 0.08) µmol Pi/10(7)/h], the Na(+)-K(+)-ATPase activity was significantly decreased in E, H and I groups [(0.24 ± 0.07), (0.25 ± 0.06) and (0.24 ± 0.07) µmol Pi/10(7)/h] (P < 0.05). Extra-erythrocytic K(+) in E, H and I groups [(2.16 ± 0.37), (2.16 ± 0.38) and (2.56 ± 0.50) mmol/L] were significantly increased compared with A group [(1.53 ± 0.43) mmol/L] (P < 0.05). Compared with A group, osmotic fragility in E, H and I groups was significantly increased (P < 0.05). Among B, C, D, E, F, G groups, only in G group colony formations of HepG2, SGC7901, and SW620 (0% ± 0%, 0% ± 0% and 0.01% ± 0.01%) at 14 d were completely inhibited (P < 0.01) compared with A group (78.54% ± 7.83%, 72.28% ± 6.58% and 66.69% ± 6.69%).
Conclusion: Pretreatment with cisplatin (50 µg/ml) plus hyperthermia (42 °C) for 60 min in vitro might be an effective strategy to clear tumor cells contamination but preserve erythrocytes, which is worthy to be optimized and used in the intra-operative blood salvage in cancer surgery.